Decheng Capital reports sale of 7,665 BYSI shares in early Oct 2025
Rhea-AI Filing Summary
Decheng Capital reporting persons, including funds managed by Dr. Xiangmin Cui, disclosed insider sales of 7,665 BeyondSpring Inc. (BYSI) ordinary shares across three days. The filings show 4,464 shares sold on 09/30/2025 at a weighted average price of about $1.81, 2,601 shares sold on 10/01/2025 at about $1.80, and 600 shares sold on 10/02/2025 at about $1.73. After the reported transactions, Decheng Capital China Life Sciences USD Fund III, L.P. is shown as beneficially owning approximately 1,838,096–1,841,297 shares (per line entries), while affiliated funds report holdings of 1,617,409 and 891,734 shares respectively. The footnotes state the prices are weighted averages within disclosed ranges and confirm the reporting chain through GP entities managed by Dr. Cui.
Positive
- Timely disclosure with a signed Form 4 filed and dated 10/02/2025
- Detailed pricing transparency via footnotes disclosing weighted average ranges and willingness to provide per‑trade detail
Negative
- Insider selling of 7,665 shares across 09/30/2025–10/02/2025
- Reduction in Fund III's reported holdings from line entries reflecting 1,841,297 to about 1,838,096 shares following sales
Insights
TL;DR: Insider sales by affiliated funds total 7,665 shares over three days; filings list indirect ownership across multiple funds.
The Form 4 shows sales executed by Decheng-related funds on 09/30/2025, 10/01/2025, and 10/02/2025, with weighted average prices reported between $1.72 and $1.83. The disclosure explicitly links ownership to Fund III, Fund II, and Healthcare vehicles and identifies Decheng Capital Management entities and Dr. Cui as the managing persons.
This filing is investor‑relevant because it clarifies the chain of beneficial ownership and the continuing indirect holdings of sizable share blocks in BeyondSpring.
TL;DR: Reported trades total 7,665 shares executed at disclosed weighted average prices within narrow ranges.
The transactions are marked with transaction code S (sale) and include footnotes specifying price ranges: $1.80–$1.83, $1.785–$1.81, and $1.72–$1.74; the filer offers to provide per‑trade detail on request. The Form 4 is signed and dated 10/02/2025, indicating timely reporting of the disposals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 600 | $1.73 | $1K |
| Sale | Ordinary Shares | 2,601 | $1.80 | $5K |
| Sale | Ordinary Shares | 4,464 | $1.81 | $8K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.785 to $1.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
